FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296618051> ?p ?o ?g. }

• W4296618051 endingPage "1857" @default.
• W4296618051 startingPage "1851" @default.
• W4296618051 abstract "Infliximab is an anti-tumour necrosis factor agent used in the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. While the use of infliximab is well established in the treatment of IBD, there are now four recently FDA-approved infliximab biosimilars that are increasingly used due to their cost-benefit for patients, institutions and payors. In addition, shortening the length of infliximab infusions from 120 min (standard infusion) to 60 min or less (rapid infusion) has been shown to safely provide further cost-benefit while also improving patient convenience. The safety of rapid infusions has been well-established for the infliximab reference product, however, there are limited data available regarding the safety of rapid infusions for infliximab biosimilars. The purpose of this study was to compare the incidence and severity of infusion reactions among patients with IBD receiving rapid infusion of infliximab reference product compared with infliximab biosimilar.This was a retrospective analysis of electronic health record data of patients with a diagnosis of IBD receiving an infliximab reference product or infliximab biosimilar infusion between December 2020 and December 2021. Patient-level variables included demographics, immunomodulator use, IBD-related hospitalization and infliximab trough concentration and antibody levels. Infusion-related variables of interest included total number of infusions, drug, dose, dosing interval, infusion time and use of pre-medications. Infusion-related reactions were defined as safety concerns documented by the administering nurse (anaphylaxis, shortness of breath, hypotension, swelling, rash, pruritus, hives, flushing, chest pain, muscle pain, joint pain, fevers, chills, headache or hypertension) or administration of emergency medications. Fisher's exact test was used to compare reaction rates.A total of 188 patients met inclusion criteria for analysis, and a total of 1124 infusions were administered during the study period. There were no statistically significant differences among any of the pre-specified outcomes. There were no differences in the incidence of infusion reactions among rapid infusion (60 min) infliximab and infliximab biosimilars (p = 0.863). Additionally, there were no differences in the incidence of infusion reactions among standard infusion (120 min) infliximab and infliximab biosimilars (p = 0.993). Finally, there were no differences among the rate of infusion reactions between rapid infusion of infliximab biosimilars and standard infusion of infliximab biosimilars (p = 0.536). Eight patients experienced safety issues, with three patients requiring emergency medications (1.6% of 188 patients).Rapid infusions of infliximab biosimilars were not associated with an increase in the incidence of infusion reactions compared with: rapid infusion of infliximab reference product, standard infusion of infliximab biosimilars, or standard infusion of infliximab reference product. This should reassure clinicians that rapid infusions of infliximab biosimilars are safe in clinical practice." @default.
• W4296618051 created "2022-09-23" @default.
• W4296618051 creator A5043392200 @default.
• W4296618051 creator A5049859994 @default.
• W4296618051 creator A5053541157 @default.
• W4296618051 creator A5057477347 @default.
• W4296618051 creator A5075796441 @default.
• W4296618051 date "2022-09-22" @default.
• W4296618051 modified "2023-10-01" @default.
• W4296618051 title "Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease" @default.
• W4296618051 cites W1554962003 @default.
• W4296618051 cites W2012597670 @default.
• W4296618051 cites W2093274439 @default.
• W4296618051 cites W2093372305 @default.
• W4296618051 cites W2141395406 @default.
• W4296618051 cites W2565061901 @default.
• W4296618051 cites W2606157605 @default.
• W4296618051 cites W2611790862 @default.
• W4296618051 cites W2744879509 @default.
• W4296618051 cites W2944434778 @default.
• W4296618051 cites W2999400123 @default.
• W4296618051 cites W3000586022 @default.
• W4296618051 cites W3165747682 @default.
• W4296618051 cites W3175207395 @default.
• W4296618051 cites W4296618051 @default.
• W4296618051 doi "https://doi.org/10.1111/jcpt.13779" @default.
• W4296618051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36134561" @default.
• W4296618051 hasPublicationYear "2022" @default.
• W4296618051 type Work @default.
• W4296618051 citedByCount "3" @default.
• W4296618051 countsByYear W42966180512022 @default.
• W4296618051 countsByYear W42966180512023 @default.
• W4296618051 crossrefType "journal-article" @default.
• W4296618051 hasAuthorship W4296618051A5043392200 @default.
• W4296618051 hasAuthorship W4296618051A5049859994 @default.
• W4296618051 hasAuthorship W4296618051A5053541157 @default.
• W4296618051 hasAuthorship W4296618051A5057477347 @default.
• W4296618051 hasAuthorship W4296618051A5075796441 @default.
• W4296618051 hasBestOaLocation W42966180511 @default.
• W4296618051 hasConcept C126322002 @default.
• W4296618051 hasConcept C141071460 @default.
• W4296618051 hasConcept C197934379 @default.
• W4296618051 hasConcept C2777138892 @default.
• W4296618051 hasConcept C2777288759 @default.
• W4296618051 hasConcept C2778260677 @default.
• W4296618051 hasConcept C2779134260 @default.
• W4296618051 hasConcept C2780479503 @default.
• W4296618051 hasConcept C42219234 @default.
• W4296618051 hasConcept C59491497 @default.
• W4296618051 hasConcept C71924100 @default.
• W4296618051 hasConceptScore W4296618051C126322002 @default.
• W4296618051 hasConceptScore W4296618051C141071460 @default.
• W4296618051 hasConceptScore W4296618051C197934379 @default.
• W4296618051 hasConceptScore W4296618051C2777138892 @default.
• W4296618051 hasConceptScore W4296618051C2777288759 @default.
• W4296618051 hasConceptScore W4296618051C2778260677 @default.
• W4296618051 hasConceptScore W4296618051C2779134260 @default.
• W4296618051 hasConceptScore W4296618051C2780479503 @default.
• W4296618051 hasConceptScore W4296618051C42219234 @default.
• W4296618051 hasConceptScore W4296618051C59491497 @default.
• W4296618051 hasConceptScore W4296618051C71924100 @default.
• W4296618051 hasIssue "11" @default.
• W4296618051 hasLocation W42966180511 @default.
• W4296618051 hasLocation W42966180512 @default.
• W4296618051 hasLocation W42966180513 @default.
• W4296618051 hasOpenAccess W4296618051 @default.
• W4296618051 hasPrimaryLocation W42966180511 @default.
• W4296618051 hasRelatedWork W2339588938 @default.
• W4296618051 hasRelatedWork W2541335332 @default.
• W4296618051 hasRelatedWork W2587460980 @default.
• W4296618051 hasRelatedWork W2972178939 @default.
• W4296618051 hasRelatedWork W2992830049 @default.
• W4296618051 hasRelatedWork W3003471368 @default.
• W4296618051 hasRelatedWork W3162050615 @default.
• W4296618051 hasRelatedWork W4234614328 @default.
• W4296618051 hasRelatedWork W4248260533 @default.
• W4296618051 hasRelatedWork W4282841296 @default.
• W4296618051 hasVolume "47" @default.
• W4296618051 isParatext "false" @default.
• W4296618051 isRetracted "false" @default.
• W4296618051 workType "article" @default.